UBS analyst John Sourbeer raised the firm’s price target on Catalent to $58 from $55 and keeps a Buy rating on the shares after its Q4 results and above-consensus FY24 guidance. The analyst notes that operational progress is being made and the company’s visibility is improving.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CTLT:
- Catalent (NYSE: CTLT) Jumps After Pact with Activist Investor Elliott
- Early notable gainers among liquid option names on August 29th
- Catalent establishes committee to conduct review, enters pact with Elliot
- Catalent adding four new independent directors as part of pact with Elliott
- Catalent confirms cooperation agreement with Elliott Investment Management